𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase I trial of liposomal doxorubicin and ZD1839 in patients with refractory gynecological malignancies or metastatic breast cancer

✍ Scribed by Susana M. Campos; Suzanne T. Berlin; Leroy M. Parker; Wendy Y. Chen; Craig A. Bunnell; Tina Atkinson; Julie Lee; Ursula Matulonis; Michelle S. Hirsch; Lyndsay Harris; Carolyn N. Krasner

Publisher
Springer
Year
2010
Tongue
English
Weight
277 KB
Volume
15
Category
Article
ISSN
1341-9625

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Phase I study of pegylated liposomal dox
Phase I study of pegylated liposomal doxorubicin and gemcitabine in patients with advanced malignancies
✍ Paula M. Fracasso; Kristie A. Blum; Benjamin R. Tan; Carole L. Fears; Nancy L. B πŸ“‚ Article πŸ“… 2002 πŸ› John Wiley and Sons 🌐 English βš– 71 KB πŸ‘ 2 views

## Abstract ## BACKGROUND Pegylated liposomal doxorubicin (PEG‐LD) and gemcitabine have single‐agent activity in breast and ovarian carcinoma patients. We conducted a Phase I trial to evaluate the maximum tolerated dose (MTD) and toxicities of this combination in patients with advanced malignancie

Phase I trial of weekly docetaxel and ge
Phase I trial of weekly docetaxel and gemcitabine in patients with refractory malignancies
✍ Tarek Mekhail; Thomas E. Hutson; Paul Elson; G. Thomas Budd; Gordon Srkalovic; T πŸ“‚ Article πŸ“… 2002 πŸ› John Wiley and Sons 🌐 English βš– 97 KB πŸ‘ 1 views

## Abstract ## BACKGROUND A Phase I study using weekly docetaxel and gemcitabine was conducted to investigate toxicity; to determine the maximum tolerated dose (MTD) of each agent; and, in a preliminary fashion, to determine the antitumor activity of the combination. ## METHODS Docetaxel and gem